We intend to focus our search on companies in the technology and financial sectors with an enterprise value of approximately $250 million to $750 million, although we may find a deal below or above that range, including firms with a nexus to Japan. Our management team has had significant success sourcing, acquiring, growing and monetizing these types […]

This is the seventh blank-check company, or special-purpose acquisition company (SPAC), founded by Michael Klein, who is perhaps best known as the former CEO of global banking at Citi. Our founder, Michael Klein, is also the founder and managing partner of M. Klein and Company, which he founded in 2012. M. Klein and Company is […]

This is the sixth blank-check company founded by Michael Klein, who is also the founder and managing partner of M. Klein and Company, which he founded in 2012. M. Klein and Company is a global strategic advisory firm that provides its clients a variety of advice tailored to their objectives. Mr. Klein was previously the CEO […]

We currently intend to concentrate our efforts in identifying businesses that provide technological innovation to the broader real estate ecosystem. As the largest asset class in the world, the real estate industry is vast and includes, but is not limited to: (i) commercial real estate such as office and industrial buildings, retail centers, stadiums and […]

We intend to focus on companies in the TMT (technology, media and telecom) and sustainable industries. Our search for targets will concentrate on companies in these sectors with enterprise values larger than $750 million. (Note: GigCapital4, Inc.’s IPO was upsized at pricing on Feb. 8, 2021, to 31.2 million units, up from 26 million, at […]

We intend to focus our search for a target business in the energy value chain in North America, with a particular focus on opportunities aligned with energy transition and sustainability themes. Our sponsor is an affiliate of a private investment fund managed by Apollo. Apollo is led by its managing partners, Leon Black, Joshua Harris […]

We intend to focus on the medical technology sector. Our management team and board (collectively referred to as the “team”) possess a synergistic combination of executive, strategic, operational, financial and transactional experience in this sector, and have demonstrated a strong track record of identifying and creating significant stockholder value at leading medical technology companies.  (Note: […]

We are a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments for hearing and balance disorders, one of the largest areas of unmet need in medicine. We aim to restore and improve hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. We have built […]

We are a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology. Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. Currently, we have two […]

Talis aims to transform diagnostic testing by developing and commercializing innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases and other conditions at the point-of-care. While timely diagnosis of infectious diseases is critically important to enable effective treatment, testing is primarily performed in centralized laboratories, which require samples […]